Stockscreener 앱 받기
98.58
1.86%
1.80
시장 영업 전:
98.58
전일 마감가:
$96.78
열려 있는:
$97.81
하루 거래량:
189.13K
Relative Volume:
0.91
시가총액:
$1.17B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.90%
1개월 성능:
+20.90%
6개월 성능:
+273.13%
1년 성능:
+0.00%
1일 변동 폭
$95.86
$99.40
1주일 범위
$95.28
$103.00
52주 변동 폭
$11.17
$106.71
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
98.58 | 1.15B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Reports Positive Topline Phase 2 Data for Qtorin Gel in Rare Skin Condition - marketscreener.com
Palvella Therapeutics Reports Positive Phase 2 Study Results - TipRanks
Palvella Therapeutics announces positive topline results from phase 2 Toiva clinical trial of Qtorin - marketscreener.com
Palvella Therapeutics Announces Positive Phase 2 TOIVA Study Results - TradingView — Track All Markets
Palvella Therapeutics Announces Positive Topline Results - GlobeNewswire
Frazier Life Sciences Management L.P. Has $16.28 Million Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Is Longfor Group Holdings Limited RLF a good long term investmentFederal Reserve Announcements & Small Investment Big Gains - earlytimes.in
Palvella Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Palvella Therapeutics (PVLA) price target increased by 15.61% to 133.70 - MSN
XTX Topco Ltd Acquires Shares of 17,701 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics initiated with a buy at Craig-Hallum - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 8% HigherStill a Buy? - MarketBeat
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Craig Hallum - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Clear Street Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
BTIG Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street Initiates Coverage on PVLA with a 'Buy' Rating | PV - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target - marketscreener.com
BTIG initiates coverage on Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Craig-Hallum Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street initiates Palvella Therapeutics stock with Buy rating, $200 target - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock beat revenue estimates2025 Price Targets & Long-Term Investment Growth Plans - Newser
How Palvella Therapeutics Inc. (PI6) stock compares with top peersJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Can Palvella Therapeutics Inc. stock sustain revenue growth2025 Volatility Report & Risk Managed Investment Signals - Newser
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock keep high P E multiplesMarket Growth Summary & Risk Managed Trade Strategies - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $117.33 Consensus PT from Brokerages - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.9%Should You Sell? - MarketBeat
Tech Rally: How risky is Palvella Therapeutics Inc stock now2025 Geopolitical Influence & Technical Entry and Exit Tips - BỘ NỘI VỤ
Palvella Therapeutics (PVLA) Stock Analysis Report | Financials & Insights - Benzinga
Will Palvella Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tiny Biotech’s Big Bet On Rare Skin Diseases - Finimize
Will Palvella Therapeutics Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - BỘ NỘI VỤ
Palvella Therapeutics stock hits 52-week high at 104.99 USD By Investing.com - Investing.com Australia
Palvella Therapeutics stock hits 52-week high at 104.99 USD - Investing.com India
Palvella Therapeutics, Inc. $PVLA Stake Reduced by Adams Street Partners LLC - MarketBeat
Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownMarket Volume Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA) - The Globe and Mail
Ready to Jump After Recent Trade: Palvella Therapeutics Inc (PVLA) - setenews.com
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 7.9%Should You Buy? - MarketBeat
Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance
Palvella Therapeutics stock price target raised to $145 by Stifel - Investing.com Canada
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 Shares of Stock - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells All Directly Owned Common Stock - TradingView
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):